An anti-inflammatory, muscle-building peptide, its preparation method and application

Scallop adductor peptides were prepared by pulsed electric field pretreatment and enzymatic hydrolysis. Combined with peptidomics and molecular docking virtual screening, peptides with anti-inflammatory and muscle-building activities were obtained. This solved the problem of limited types of food-derived anti-inflammatory and muscle-building peptides, and achieved significant reduction of inflammatory factor expression and activation of anti-inflammatory signaling pathways, thus promoting muscle growth.

CN123106828APending Publication Date: 2026-11-17NINGBO UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611466539.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-20
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies have limited types of food-derived anti-inflammatory and muscle-building bioactive peptides, insufficient research on marine-derived bioactive peptides, low bioactive peptide screening efficiency, and difficulty in effectively alleviating inflammation-related muscle atrophy.

Method used

Scallop adductor peptides were prepared using pulsed electric field pretreatment combined with enzymatic hydrolysis. Two peptides with anti-inflammatory and muscle-building activities were obtained by using peptidomics and molecular docking virtual screening. Through peptide identification and cell experiments, peptides with anti-inflammatory and muscle-building activities were screened out.

Benefits of technology

It significantly reduced the expression levels of TNF-α, IL-6 and IL-1β, activated the Nrf2/HO-1 signaling pathway, inhibited the activation of the Smad2/3 signaling pathway, promoted the proliferation of C2C12 myoblasts, improved LPS-induced cellular inflammatory damage, and improved muscle atrophy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106828A_ABST
    Figure CN123106828A_ABST
Patent Text Reader

Abstract

This invention discloses an anti-inflammatory and muscle-building peptide, its preparation method, and its applications. The amino acid sequences of the anti-inflammatory and muscle-building peptide are shown in SEQ ID NO:1 (HELEEAEER) and SEQ ID NO:2 (SDYDNLN). The peptide can reduce the expression levels of TNF-α, IL-6, and IL-1β, activate the Nrf2 / HO-1 signaling pathway, and inhibit the activation of the Smad2 / 3 signaling pathway. This invention prepares scallop peptides through pulsed electric field pretreatment combined with enzymatic hydrolysis. Using peptidomics, molecular docking virtual screening, and cell experiments, two peptide fragments with anti-inflammatory and muscle-building activities were obtained, providing a new technical approach for the development and utilization of marine-derived functional peptides.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the interdisciplinary field of bioengineering and food processing, and particularly relates to an anti-inflammatory, muscle-building peptide, its preparation method, and its application. Background Technology

[0002] Muscle atrophy is a pathological process characterized by a decline in skeletal muscle mass and function, caused by factors such as aging, inflammation, malnutrition, and various diseases, severely impacting human health and quality of life. Studies have shown that inflammation is a significant factor inducing muscle atrophy. Inflammatory stimuli such as lipopolysaccharide (LPS) can promote the expression of inflammatory factors such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), while simultaneously activating myostatin and its downstream Smad2 / 3 signaling pathways, thereby promoting muscle protein degradation and accelerating muscle atrophy. Therefore, developing safe and effective natural active substances to alleviate inflammation-related muscle atrophy is of great significance.

[0003] Scallop adductor muscle (MAS) is an important edible tissue in scallop processing. Rich in high-quality myofibrillar proteins such as myosin heavy chains, actin, tropomyosin, and troponin, it is an excellent source of raw materials for preparing bioactive peptides. Bioactive peptides are small-molecule peptides produced by enzymatic hydrolysis of proteins, possessing advantages such as high safety, good bioavailability, and easy absorption. In recent years, dietary peptides have received widespread attention due to their anti-inflammatory and immunomodulatory activities. However, current research on dietary peptides in alleviating inflammation-related muscle atrophy is still limited. Reported bioactive peptides are mainly derived from milk protein, soy protein, and livestock and poultry meat proteins; the development and application of marine-derived bioactive peptides require further research. Summary of the Invention

[0004] To address the current limitations of limited types of food-derived anti-inflammatory and muscle-building peptides, insufficient research on marine-derived bioactive peptides, and low screening efficiency for bioactive peptides, this invention provides an anti-inflammatory and muscle-building peptide derived from scallop adductor muscles, its preparation method, and its applications. Scallop adductor peptides are prepared using pulsed electric field pretreatment combined with enzymatic hydrolysis. Through peptidomics, molecular docking virtual screening, and cell experiments, two peptide fragments with anti-inflammatory and muscle-building activities were obtained, providing a new technical approach for the development and utilization of marine-derived functional peptides.

[0005] To achieve the above objectives, the present invention adopts the following technical solution:

[0006] I. A scallop adductor peptide with anti-inflammatory and muscle-building activities, wherein the amino acid sequence of the scallop adductor peptide with anti-inflammatory and muscle-building activities is shown in SEQ ID NO:1 (HELEEAEER) and SEQ ID NO:2 (SDYDNLN). The peptide can reduce the expression levels of TNF-α, IL-6, and IL-1β, activate the Nrf2 / HO-1 signaling pathway, and inhibit the activation of the Smad2 / 3 signaling pathway.

[0007] II. This invention provides a method for preparing scallop adductor peptides with anti-inflammatory and muscle-building activities, comprising the following steps:

[0008] (1) After pretreatment of the scallop adductor material, pulsed electric field treatment was carried out, and papain and trypsin were used in sequence for two-step enzymatic hydrolysis to obtain scallop adductor hydrolysis product.

[0009] (2) The peptides in the enzymatic hydrolysis products were identified by liquid chromatography-mass spectrometry, and a peptide library was established;

[0010] (3) Using the crystal structures of Kelch-like ECH-related protein 1 and type IIB activin receptor as targets, peptides with low binding energy and potential anti-inflammatory and muscle-building activities were virtually screened from the peptide library by molecular docking technology.

[0011] (4) The candidate peptides were synthesized and screened out as anti-inflammatory and muscle-building peptides through cell experiments.

[0012] In step (1), the electric field strength of the pulsed electric field treatment is 1~3 kV / cm. The solid-liquid ratio of the raw materials before enzymatic hydrolysis is 1:6~1:10, the amount of papain added is 2%~6%, the enzymatic hydrolysis time of papain is 1.5~2.5 h, the amount of trypsin added is 2%~6%, and the enzymatic hydrolysis time of trypsin is 1.5~2.5 h.

[0013] The most preferred method for preparing the above-mentioned anti-inflammatory and muscle-building peptides includes the following steps:

[0014] (1) Pretreatment of scallop adductor muscle and pulsed electric field pretreatment: Fresh scallop adductor muscles were taken, cleaned, cooked and minced, and then subjected to pulsed electric field (PEF) pretreatment. PEF treatment was carried out using a laboratory high-voltage pulsed electric field device. By adjusting the applied voltage to 10, 20 and 30 kV, electric field intensities of 1, 2 and 3 kV / cm were obtained, and the treatment time was 30 s. The pulse width and pulse frequency were kept unchanged at the instrument's default settings, and only the electric field intensity was changed as the experimental variable. According to the different electric field intensities, the samples were recorded as SAM-E (0 kV / cm), SAM-P1-E (1 kV / cm), SAM-P2-E (2 kV / cm) and SAM-P3-E (3 kV / cm), respectively. After PEF treatment, enzymatic hydrolysis was immediately carried out according to the optimized two-step enzymatic hydrolysis method.

[0015] (2) Determination of enzymatic hydrolysis conditions

[0016] ① Virtual enzymatic hydrolysis

[0017] Myosin heavy chain and actin are the main proteins in scallop adductor muscles. Therefore, this study obtained the amino acid sequences of myosin heavy chain (UniProt ID: A0A210Q4H2) and actin (UniProt ID: A0A210Q4N6) from the UniProt database (https: / / www.uniprot.org).

[0018] This invention selects five commonly used commercial proteases for virtual enzymatic hydrolysis experiments: pepsin, trypsin, alkaline protease, papain, and bromelain. Using the potential bioactivity map module and enzymatic hydrolysis tools in the BIOPEP-UWM database, in vitro simulated enzymatic hydrolysis of these four proteins was performed. The hydrolysis results of different enzyme combinations, including single-step hydrolysis and two-step combined hydrolysis, were recorded.

[0019] The frequency of bioactive peptide generation under different enzymatic hydrolysis strategies was statistically analyzed and expressed as activity release efficiency (AE). Activity release efficiency was calculated according to formula (1):

[0020]

[0021] In the formula: d is the number of peptides with specific biological activities released from the protein sequence after action by a single enzyme or a complex enzyme; N is the total number of amino acid residues in the corresponding protein sequence.

[0022] ② Screening and validation of candidate enzymatic digestion schemes

[0023] Based on the virtual enzymatic hydrolysis prediction results from the BIOPEP database, five two-step enzymatic hydrolysis strategies with high predicted AE values ​​were selected for actual hydrolysis verification. The selected enzymatic hydrolysis combinations included pepsin-trypsin (Pep-Try), pepsin-papain (Pep-Pap), pepsin-bromelain (Pep-StBro), trypsin-papain (Try-Pap), and trypsin-bromelain (Try-StBro). Scallop adductor enzyme hydrolysates were prepared according to the optimal reaction conditions for each enzyme and then lyophilized for later use. C2C12 cell viability was used as an evaluation index to preliminarily screen the bioactivity of different enzymatic hydrolysates. C2C12 myoblasts were purchased from Hangzhou Baidi Biotechnology Co., Ltd., China. The high-glucose DMEM medium used for cell culture was purchased from Gibco (Thermo Fisher Scientific), USA, and supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin antibiotics. Cells were incubated at 37 ℃ in a 5% CO2 saturated humidity incubator for 24 h until cell adhesion occurred; then, at a concentration of 1.5 × 10⁻⁶ cells / mL, the cells were incubated at a concentration of 1.5 × 10⁻⁶ cells / mL. 4 Cells were seeded at a density of 1 cell / well in 96-well plates and cultured for 24 h. Then, 1 mg / mL of enzyme was added to digest the sample for another 24 h. Cell viability was detected using a CCK-8 assay kit (Boster Biological Engineering Co., Ltd., Wuhan, China). The procedure is briefly described as follows: 10 μL of CCK-8 working solution was added to each well of the cell system to be tested, and the cells were incubated at 37 ℃ in the dark for 1 h. The absorbance of each well was measured at 450 nm using a microplate reader, and cell viability was calculated based on the absorbance values.

[0024] ③ Two-step enzymatic hydrolysis method

[0025] Scallop adductor muscles were heated in boiling water for 10 minutes, cooled, and then adjusted to the optimal pH for the enzyme using 0.1 mol / L sodium hydroxide solution. Hydrolysis was performed using two enzymes (papain-trypsin or trypsin-papain), each supplemented at 2%. The entire enzymatic hydrolysis process was carried out in a constant-temperature water bath at the optimal temperature for the corresponding protease, with stirring, while maintaining the pH of the system at the optimal pH for the corresponding protease. The duration of each single-step hydrolysis step was 2 hours. After hydrolysis, the supernatant was collected by centrifugation and freeze-dried to obtain scallop adductor peptides. Centrifugation conditions were 10,000 rpm for 20 minutes, and freeze-drying conditions were pre-freezing at -80°C for 12 hours followed by freeze-drying for 48 hours. The C2C12 cell viability of the scallop adductor peptides was measured to determine the hydrolysis sequence. Subsequently, the enzyme-to-substrate ratio remained constant, and the hydrolysis time for papain and trypsin was 2 hours. The variables were the solid-liquid ratio (1:4, 1:6, 1:8, 1:10, 1:12), and the index was C2C12 cell viability. Subsequently, keeping other conditions constant, the levels of papain added (2%, 4%, 6%, 8%, 10%) and hydrolysis times (1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours) were investigated, with C2C12 cell viability as the index. Similarly, with other conditions constant, the levels of trypsin added (2%, 4%, 6%, 8%, 10%) and hydrolysis times (1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours) were investigated, and C2C12 cell viability was selected as the indicator.

[0026] The application of the anti-inflammatory and muscle-building scallop adductor peptide in the preparation of muscle damage repair-related products.

[0027] This invention provides a method for preparing scallop adductor peptides. The method involves treating scallop adductor mince with pulsed electric fields of different electric field strengths for 30 seconds, and then using virtual enzymatic hydrolysis and single-factor optimization to screen out a better two-step enzymatic hydrolysis method to obtain scallop adductor peptides with good biological activity.

[0028] This invention provides a method for preparing scallop adductor peptides, the steps of which are as follows:

[0029] (1) Scallop adductor peptides were prepared by physical field pretreatment combined with a two-step enzymatic hydrolysis method;

[0030] The shredded scallop adductor muscle is treated with a high-voltage pulsed electric field; the electric field strength of the pulsed electric field treatment is 1~3kV / cm.

[0031] Furthermore, a two-step enzymatic hydrolysis method was adopted, first using papain and then trypsin. The solid-liquid ratio of the raw materials before enzymatic hydrolysis was 1:6 to 1:10, the amount of papain added was 2% to 6%, the enzymatic hydrolysis time of papain was 1.5 to 2.5 h, the amount of trypsin added was 2% to 6%, and the enzymatic hydrolysis time of trypsin was 1.5 to 2.5 h.

[0032] (2) Peptide identification and peptide library establishment: Peptides in the enzyme hydrolysates prepared by pulsed electric field assisted enzymatic hydrolysis at 0 kV / cm, 1 kV / cm, 2 kV / cm and 3 kV / cm were identified by liquid chromatography-mass spectrometry. A peptide library containing multiple peptides was established by searching the Scallop family protein database.

[0033] (3) Molecular docking virtual screening: Using the crystal structure of ActRIIB (type IIB activin receptor) (PDB ID: 5NGV) and the crystal structure of Keap1 (Kelch-like ECH-associated protein 1) (PDB ID: 2FLU) as targets, molecular docking software (such as Discovery Studio) is used to dock peptides in the peptide library to the active site of the receptor, and candidate peptides are screened according to the binding energy.

[0034] (4) The anti-inflammatory and myotrophic peptides were verified using a mouse myoblast model.

[0035] Cell proliferation experiments were conducted using a C2C12 mouse myoblast model to evaluate the effects of candidate peptides on cell proliferation activity.

[0036] Lipopolysaccharide (LPS) was used to induce inflammatory damage in C2C12 cells to construct an in vitro muscle atrophy cell model.

[0037] The expression levels of inflammatory factors tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) were detected using an ELISA kit.

[0038] Western blotting was used to detect the expression levels of proteins related to the Nrf2 / HO-1 signaling pathway and to evaluate the activation effect of candidate peptides on the Nrf2 / HO-1 signaling pathway. At the same time, the expression levels of proteins related to the Smad2 / 3 signaling pathway were detected to evaluate the inhibitory effect of candidate peptides on the Smad2 / 3 signaling pathway.

[0039] Third, this invention combines peptidomics technology and virtual screening technology to identify the structures of anti-inflammatory and muscle-building peptides, obtaining the sequences of nine anti-inflammatory and muscle-building peptides as described above and verifying their activity.

[0040] IV. This invention provides a composition comprising the above-mentioned muscle-building peptides and a food-grade acceptable carrier. This composition can be a functional food, for example, in the form of nutrition bars, protein powder, tablets, capsules, or beverages.

[0041] V. This invention provides the use of the above-mentioned muscle-building peptide or compositions containing it in the preparation of products for the prevention and / or treatment of sarcopenia. The products exert their effects by activating the expression of the Nrf2 / HO-1 signaling pathway and inhibiting phosphorylation of the Smad2 / 3 signaling pathway.

[0042] Compared with the prior art, the advantages of the present invention are as follows:

[0043] (1) Excellent bioactivity: The active peptides provided by this invention can significantly promote the proliferation of C2C12 myoblasts, and the cell proliferation rate is more than 40% higher than that of the control group. At the same time, it can improve LPS-induced inflammatory damage to C2C12 cells, reduce the expression levels of inflammatory factors such as TNF-α, IL-6 and IL-1β, and exert muscle protection by regulating Nrf2 / HO-1 and myosin-related signaling pathways.

[0044] (2) Safe source and easy to absorb: The peptides described in this invention are derived from scallop adductor muscles, which are commonly consumed, and are prepared through enzymatic hydrolysis. The source is clear and the safety basis is good. As they are small molecule active peptides from natural sources, they have good biocompatibility and oral application potential, which provides favorable conditions for their development and application in nutritional supplements, functional foods and related health products.

[0045] (3) Broad application prospects: The anti-inflammatory and muscle-building peptides provided by this invention can be used as key functional ingredients and widely used in the development of nutritional supplements and health foods for middle-aged and elderly people with inflammatory muscle atrophy, sports injury recovery, etc., which have important market value and social benefits. Attached Figure Description

[0046] Table 1. Virtual hydrolysis predictions based on different enzymatic hydrolysis strategies using the BIOPEP database.

[0047] Table 2 shows the docking results of the top 9 candidate peptides with the highest binding energies to Keap1 and ActRIIB receptors obtained from molecular docking screening.

[0048] Table 3 shows the effects of nine candidate peptides at different concentrations on the proliferation rate of C2C12 cells.

[0049] Figure 1 This is a diagram showing the single-factor optimization results of various enzymatic hydrolysis parameters in the pulsed electric field-assisted enzymatic hydrolysis process of the present invention.

[0050] Figure 2Figure 1 shows the results of measuring the degree of hydrolysis, peptide concentration, molecular weight distribution, and effects on C2C12 cell viability of scallop adductor enzymatic hydrolysis products under different pulsed electric field intensities.

[0051] Figure 3 This is a distribution diagram of the main source proteins of peptides identified in the enzymatic hydrolysis products of scallop adductor muscles obtained after pretreatment with a 2 kV / cm pulsed electric field and enzymatic hydrolysis.

[0052] Figure 4 The figure shows the regulatory effects of nine candidate peptides on the expression levels of inflammatory factors.

[0053] Figure 5 The figure shows the results of measuring the effects of the selected dominant peptides (HELEEAEER, SDYDNLN) on Nrf2 / HO-1 protein expression and Smad2 / 3 phosphorylation levels. Detailed Implementation

[0054] The present invention will be further described in detail below with reference to specific embodiments and accompanying drawings. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Experimental methods in the following embodiments, unless otherwise specified, are generally performed under conventional conditions in the art or as recommended by the manufacturer.

[0055] Example 1: Optimization of enzymatic hydrolysis process parameters and screening of optimal enzymatic hydrolysis products assisted by pulsed electric field pretreatment of scallop adductor muscles

[0056] 1.1 Scallop adductor pretreatment: Scallop adductor purchased from local supermarkets was rinsed with distilled water, boiled for 10 minutes, and then minced with a meat grinder until the particle size was no larger than 1cm.

[0057] 1.2 Pulsed Electric Field Treatment: Pulsed electric field treatment was performed using a laboratory high-voltage pulsed electric field device. By adjusting the applied voltage to 10, 20, and 30 kV, electric field strengths of 1, 2, and 3 kV / cm were obtained, with a treatment time of 30 s for each. The pulse width and pulse frequency remained at the instrument's default settings; only the electric field strength was varied as the experimental variable. Based on the different electric field strengths, the samples were designated as SAM-E (0 kV / cm), SAM-P1-E (1 kV / cm), SAM-P2-E (2 kV / cm), and SAM-P3-E (3 kV / cm), respectively. Immediately after PEF treatment, enzymatic digestion was performed using the optimized two-step enzymatic digestion method.

[0058] 1.3 Optimization of Enzymatic Hydrolysis Process Parameters

[0059] (1) Virtual enzymatic digestion: Myosin heavy chain and actin are the main proteins in scallop adductor muscle. Therefore, the amino acid sequences of myosin heavy chain (UniProt ID: A0A210Q4H2) and actin (UniProt ID: A0A210Q4N6) were obtained from the UniProt database (https: / / www.uniprot.org).

[0060] This study selected five commonly used commercially available proteases for virtual enzymatic hydrolysis experiments. All five were purchased from Shanghai Yuanye Biotechnology Co., Ltd.: pepsin (CAS: 9001-75-6), trypsin (CAS: 9002-07-7), alkaline protease (CAS: 9014-01-1), papain (CAS: 9001-73-4), and bromelain (CAS: 37189-34-7). The potential bioactivity profile module and enzymatic hydrolysis tools in the BIOPEP-UWM database were used to simulate enzymatic hydrolysis of these five proteins in vitro. The hydrolysis results were recorded for different enzyme combinations, including single-step hydrolysis and two-step combined hydrolysis.

[0061] The frequency of bioactive peptide generation under different enzymatic hydrolysis strategies was statistically analyzed and expressed as activity release efficiency (AE). Activity release efficiency was calculated according to formula (1):

[0062]

[0063] In the formula: d is the number of peptides with specific biological activities released from the protein sequence after action by a single enzyme or a complex enzyme; N is the total number of amino acid residues in the corresponding protein sequence.

[0064] The results are shown in Table 1. Based on the virtual enzymatic hydrolysis prediction results of the BIOPEP database, five two-step enzymatic hydrolysis strategies with high predicted AE values ​​were selected for actual hydrolysis verification. The enzymatic hydrolysis combinations obtained by screening included two-step enzymatic hydrolysis combinations of pepsin-trypsin (Pep-Try), pepsin-papain (Pep-Pap), pepsin-bromelain (Pep-StBro), trypsin-papain (Try-Pap), and trypsin-bromelain (Try-StBro).

[0065] Table 1

[0066]

[0067] (2) Screening and validation of candidate enzymatic hydrolysis schemes: Based on the virtual enzymatic hydrolysis prediction results of the BIOPEP database, five two-step enzymatic hydrolysis strategies with high predicted AE values ​​were selected for actual hydrolysis validation. Scallop adductor hydrolysis products were prepared according to the optimal reaction conditions of each enzyme and freeze-dried for later use. C2C12 cell viability was used as an evaluation index to preliminarily screen the bioactivity of different enzymatic hydrolysis products.

[0068] The results are as follows Figure 1 As shown in (a): Among the five enzymatic digestion methods investigated, the enzymatic digest obtained by two-step digestion with trypsin and papain showed the most significant promoting effect on the viability of C2C12 cells, and was significantly different from other enzymatic digestion methods (P < 0.05). Therefore, this two-step digestion method was selected as the enzymatic digestion process for the subsequent preparation of functional peptides.

[0069] (3) Two-step enzymatic hydrolysis: Scallop adductor muscles were heated in boiling water for 10 minutes, cooled, and then adjusted to the optimal pH value of the enzyme using 0.1 mol / L sodium hydroxide solution. Two enzymes (papain-trypsin or trypsin-papain) were used for hydrolysis, each supplemented at 2%. The entire enzymatic hydrolysis process was carried out in a constant temperature water bath at the optimal temperature of the corresponding protease, while maintaining the pH of the system at the optimal pH of the corresponding protease. The duration of each enzymatic hydrolysis step was 2 h. After enzymatic hydrolysis, the supernatant was collected by centrifugation and freeze-dried to obtain scallop adductor peptides. The centrifugation conditions were 10,000 rpm for 20 minutes, and the freeze-drying conditions were pre-freezing at -80°C for 12 hours followed by freeze-drying for 48 hours. The C2C12 cell viability of the scallop adductor peptides was measured to determine the enzymatic hydrolysis sequence. Subsequently, with the enzyme-to-substrate ratio kept constant, the enzymatic hydrolysis time for papain and trypsin was 2 hours, with the solid-liquid ratio (1:4, 1:6, 1:8, 1:10, 1:12) as the variable and C2C12 cell viability as the index. Then, with other conditions unchanged, the papain addition amount (2%, 4%, 6%, 8%, 10%) and enzymatic hydrolysis time (1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours) were investigated, with C2C12 cell viability as the index. Similarly, with other conditions unchanged, the trypsin addition amount (2%, 4%, 6%, 8%, 10%) and enzymatic hydrolysis time (1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours) were investigated, and C2C12 cell viability was selected as the indicator.

[0070] The results are as follows Figure 1 As shown: Figure 1(b) By comparing the effects of different two-enzyme hydrolysis sequences on the viability of C2C12 cells, it was found that the hydrolysate obtained by pre-hydrolyzing with papain followed by secondary hydrolysis with trypsin had a significantly better promoting effect on the viability of C2C12 cells than the reverse hydrolysis sequence, and the difference was statistically significant (P < 0.05). Therefore, the two-step hydrolysis process of "papain-trypsin" was determined to be used for subsequent experiments.

[0071] like Figure 1 As shown in (cg), the optimal enzymatic hydrolysis conditions were further optimized as follows: a solid-liquid ratio of 1:8, a papain addition of 4%, and a hydrolysis time of 2 h; subsequently, 2% trypsin was added for a second hydrolysis, with a hydrolysis time of 2 h. The enzymatic hydrolysate obtained under the above conditions was used for the subsequent preparation and screening of functional peptides.

[0072] 1.4 Index Measurement and Result Analysis: The degree of hydrolysis, peptide concentration, and molecular weight distribution of products with different pulsed electric field intensities (such as SAM-E (0 kV / cm), SAM-P1-E (1 kV / cm), SAM-P2-E (2 kV / cm), and SAM-P3-E (3 kV / cm)) were measured and their effects on the viability of C2C12 myoblasts were evaluated.

[0073] The results are as follows Figure 2 As shown, the degree of hydrolysis and peptide concentration of scallop adductor muscle dynamically changed with the electric field strength during enzymatic hydrolysis at different electric field intensities. Considering all indicators, the product with the highest degree of hydrolysis (37.07% ± 5.65%) and peak peptide concentration (304.20 ± 18.77 μg / mL) was obtained with a pulsed electric field strength of 2 kV / cm (SAM-P2-E). Furthermore, this product most significantly enhanced the viability of C2C12 myoblasts (135.51% ± 4.73%). Therefore, the SAM-P2-E hydrolysate was identified as the optimal raw material for subsequent screening of functional peptides.

[0074] like Figure 3 As shown, mass spectrometry identification and source analysis of the SAM-P2-E enzymatic hydrolysate revealed that the identified peptides mainly originated from actin and myosin light chains.

[0075] Example 2: Screening of anti-inflammatory and muscle-building peptides based on Keap1 and ActRIIB receptor molecular docking

[0076] 2.1 Peptide Identification and Peptide Library Construction: Enzymatic hydrolysates treated with different pulsed electric field intensities were desalted via 3 kDa ultrafiltration and then identified as peptides using NanoLC-Orbitrap MS / MS. Chromatographic separation was performed using an Acclaim PepMap RSLC C18 column (75 μm × 25 cm). Mobile phase A was 0.1% formic acid aqueous solution, and mobile phase B was 0.1% formic acid acetonitrile solution, with gradient elution (0–30 min, 5%–35% B). Mass spectrometry analysis was performed in positive ion mode, with a Full MS resolution of 70,000 and an MS / MS resolution of 17,500, with a scan range of m / z 350–1800. PEAKS Studio 8.5 software was used to search the Scallop family protein sequence database, identifying 7347 peptides, which were used to construct a peptide library for virtual screening.

[0077] 2.2 Virtual Screening for Molecular Docking: Peptides were ranked by abundance based on the average peak area of ​​peptides in each group of samples. Peptides with peak areas higher than the group average were screened, resulting in 2374 high-abundance peptides for subsequent molecular docking analysis. The crystal structures of Keap1 (PDB ID: 2FLU) and ActRIIB (PDB ID: 5NGV) were obtained from the Protein Database (PDB). The receptor proteins were preprocessed using Discovery Studio 2019 software to remove water molecules and original ligands. Subsequently, the three-dimensional structures of peptides in the peptide library were minimized using the CHARMM force field. The CDOCKER module in Discovery Studio 2019 was used to dock the peptides to the active sites of Keap1 and ActRIIB, respectively. The grid center coordinates for the Keap1 active site were set to x = 5.000222, y = 7.103889, z = 5.058000, with a grid radius of 10 Å; the grid center coordinates for the ActRIIB active site were set to x = -4.88774, y = 10.2925, z = 15.3631, with a grid radius of 20.6 Å. The docking results were ranked using the CDOCKER binding energy as an evaluation metric. Since lower binding energy indicates higher binding stability and stronger interaction between the peptide and the receptor, the peptides were screened from lowest to highest binding energy with Keap1, ultimately obtaining the top 9 candidate active peptides for subsequent analysis.

[0078] Table 2 shows the molecular docking results and binding energies of the top 9 candidate peptides with the Keap1 and ActRIIB receptors.

[0079] Table 2

[0080]

[0081] Example 3: Verification of the cellular activity of anti-inflammatory and muscle-building peptides

[0082] 3.1 Cell proliferation assay: C2C12 mouse myoblasts were cultured in high-glucose DMEM medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin, and incubated at 37°C in a 5% CO2 incubator. When the cells reached 70%-80% confluence, the medium was replaced with medium containing different concentrations (12.5, 50, 100 μM) of synthetic peptides for 24 hours. A control group without peptides and a positive control group with IGF-1 were also included. After treatment, 10 μL of CCK-8 reagent was added to each well, and the cells were incubated at 37°C for 1 hour. The absorbance at 450 nm was measured using a microplate reader, and the relative cell proliferation rate was calculated.

[0083] 3.2 ELISA detection of inflammatory cytokine levels: C2C12 cells were cultured to a confluence of 80%–90%, then induced to differentiate using high-glucose DMEM differentiation medium containing 2% horse serum. The medium was changed every two days for 7 consecutive days to form mature myotubes. Mature myotubes were treated with 1 μg / mL LPS for 24 h to construct an inflammatory injury model; subsequently, the optimal concentration of a candidate active peptide (100 μM) validated in previous experiments was added, and the cells were cultured for another 24 h. After treatment, the culture supernatant was collected, and the expression levels of inflammatory cytokines such as TNF-α, IL-6, and IL-1β were measured according to the ELISA kit instructions.

[0084] 3.3 Western blot analysis: C2C12 cells were cultured to a confluence of 80%–90%, then induced to differentiate using high-glucose DMEM differentiation medium containing 2% horse serum. The medium was changed every two days for 7 consecutive days to form mature myotubes. Mature myotubes were treated with 2.5 μg / mL LPS for 24 h to construct an inflammatory injury model; subsequently, the optimal concentration of candidate bioactive peptides was added for another 24 h. Cells were collected and total protein was extracted using RIPA lysis buffer. Equal volumes of protein samples were separated by SDS-PAGE electrophoresis and transferred to PVDF membranes. After blocking with 5% skim milk, the membranes were incubated overnight at 4°C with specific primary antibodies (including p-Smad2 / 3, t-Smad2 / 3, Nrf2, HO-1, and GAPDH antibodies). After washing, the membranes were incubated with HRP-labeled secondary antibody at room temperature for 1 hour. Finally, ECL chemiluminescence substrate was used for color development, and the protein bands were analyzed using ImageJ software.

[0085] The results are as follows Figure 4 , Figure 5As shown in Table 3: Table 3 illustrates the effects of nine candidate bioactive peptides on the proliferation rate of C2C12 cells. The results indicate that all nine candidate peptides promoted C2C12 cell proliferation in a concentration-dependent manner. Among them, SEQ ID NO:1 (HR-9) exhibited the most significant proliferative effect at a concentration of 100 μM, achieving a cell viability of 144.25% ± 3.81%. Figure 4 ELISA results (ac) showed that five peptides—HR-9, SN-7, DK-7, AR-7, and DE-6—significantly inhibited the excessive secretion of three pro-inflammatory cytokines. HR-9 reduced the secretion of IL-6, TNF-α, and IL-1β by 45.54%, 43.84%, and 37.45%, respectively, while SN-7 showed the strongest inhibitory effect on IL-6 (48.77%), effectively alleviating LPS-induced cellular inflammatory stress. Based on the cell experiments, the three peptides with superior activity were further selected for mechanistic studies. Figure 5 Western blot results and statistical analysis of (ad) showed that, compared with the model group, both HR-9 and SN-7 peptides significantly increased the expression levels of Nrf2 and HO-1 proteins. Figure 5 Western blot results and statistical analysis of (e,f) showed that treatment with both HR-9 and SN-7 peptides significantly reduced the p-Smad2 / 3 to t-Smad2 / 3 ratio. These results indicate that the bioactive peptides screened in this invention can activate the Nrf2 / HO-1 signaling pathway, enhancing cellular antioxidant and anti-inflammatory capabilities; simultaneously, they inhibit the activation of the myostatin-related Smad2 / 3 signaling pathway, thereby alleviating inflammatory damage and promoting myocyte differentiation and growth.

[0086] Table 3

[0087]

Claims

1. An anti-inflammatory, muscle-building peptide, characterized in that, The amino acid sequences of the anti-inflammatory and muscle-building peptides are shown in SEQ ID NO:1 or SEQ ID NO:2; SEQ ID NO:1 is HELEEAEER; SEQ ID NO:2 is SDYDNLN.

2. The anti-inflammatory and myotrophic peptide according to claim 1, characterized in that, The peptide can reduce the expression levels of TNF-α, IL-6 and IL-1β, activate the Nrf2 / HO-1 signaling pathway, and inhibit the activation of the Smad2 / 3 signaling pathway.

3. A method for preparing the anti-inflammatory, myotrophic peptide according to claim 1 or 2, characterized in that, Includes the following steps: (1) After pretreatment of the scallop adductor material, pulsed electric field treatment was carried out, and papain and trypsin were used in sequence for two-step enzymatic hydrolysis to obtain scallop adductor hydrolysis product. (2) The peptides in the enzymatic hydrolysis products were identified by liquid chromatography-mass spectrometry, and a peptide library was established; (3) Using the crystal structures of ActRIIB and Keap1 as targets, potential anti-inflammatory and muscle-building peptides with low binding energy were virtually screened from the peptide library by molecular docking technology. (4) The candidate peptides were synthesized and screened out as anti-inflammatory and muscle-building peptides through cell experiments.

4. The preparation method according to claim 3, characterized in that, In step (1), the electric field strength of the pulsed electric field treatment is 1~3 kV / cm.

5. The preparation method according to claim 3, characterized in that, In step (1), the enzymatic hydrolysis time of papain is 1.5~2.5 h; the enzymatic hydrolysis time of trypsin is 1.5~2.5 h.

6. A composition, characterized in that, It includes the anti-inflammatory, muscle-building peptides as described in claim 1 or 2, and a food-grade acceptable carrier.

7. The composition according to claim 5, characterized in that, The composition is a functional food, and the dosage form of the functional food is a nutrition bar, protein powder, tablet or capsule.

8. The use of the anti-inflammatory, muscle-building peptide of claim 1 or 2, or the composition of claim 5 or 6, in the preparation of a product for the prevention and / or treatment of sarcopenia.

9. The use of the anti-inflammatory or myotrophic peptide of claim 1 or 2, or the composition of claim 5 or 6, in the preparation of products for promoting myoblast proliferation, inhibiting muscle atrophy, or improving muscle function.

10. The application according to claim 8 or 9, characterized in that, The product works by activating the expression of the Nrf2 / HO-1 signaling pathway and inhibiting the phosphorylation of the Smad2 / 3 signaling pathway.